Published Date: 16 Feb 2023
Chatbots have shields to control misinformation, but it will continue to be a game.
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
The combination of nitedanib and prednisone reduces exacerbations of pulmonary diseases in radiative pneumonitis
2.
In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.
3.
A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.
4.
Lung nodules seen in a high percentage of non-smokers
5.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
1.
Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma
2.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
3.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
4.
Unveiling Tumor Immunity: Pan-Cancer Proteogenomics Characterization
5.
Exploring the Causes and Treatment of Granulocytopenia: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation